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associated with the clinical features and
prognosis of gastric cancer
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Abstract
Background: To study the association between Apelin expression and the clinical features and postoperative
prognosis in patients with gastric cancer (Int J Cancer 136:2388-2401, 2015).
Methods: Tumor samples and matched adjacent normal tissues were collected from 270 patients with GC
receiving surgical resection. The tumor and serum Apelin levels were determined by immunohistochemistry and
ELISA methods, respectively. GC cell lines were cultured for migration and invasive assays.
Results: Our data showed that tumor Apelin expression status, instead of serum Apelin level, was closely associated
with more advance clinical features including tumor differentiation, lymph node and distant metastases. Moreover,
patients with high tumor Apelin level had a significantly shorter overall survival period compared to those with low
Apelin expression and those with or negative Apelin staining. Our in vitro study revealed that the Apelin regulated
the migration and invasion abilities of GC cell lines, accompanied by up-regulations of a variety of cytokines
associated with tumor invasiveness.
Conclusion: Our data suggest that tumor Apelin can be used as a marker to evaluate clinical characteristics and
predict prognosis in GC patients.
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Background
Gastric cancer is among the leading causes of global
cancer-related mortality [1]. Despite of the recent ad-
vances in diagnosis and therapy, the prognosis of GC pa-
tients is still poor. Usually, the 5-year survival rates are
less than 20 % [2–4]. Currently, there is no specific
marker for early diagnosis and prognosis prediction, al-
though a number of proteins have been previously re-
ported to be associated with the outcome of GC patients
[5–8].
Apelin is a member of the endogenous ligand of the
human G protein receptor, known as APJ [9]. Both
Apelin and APJ are extensively expressed in blood
vasculature and stimulate angiogenesis by prompting
endothelial cell growth [10–12]. Also, Apelin induces
the maturation of tumor blood capillaries and prompts
tumor vascularization [13]. Moreover, Apelin is upregu-
lated in human cancers and its association with cancer
outcomes were reported as well [14–17]. In addition, re-
cent studies show that Apelin has lymphangiogenic po-
tential and it is related to tumor growth and lymph node
metastasis in vivo [18, 19].
However, the association of Apelin and gastric cancer
remain largely unknown. A recent study reported a
higher serum Apelin in patients with gastroesophageal
cancer (GEC) compared to healthy controls [20]. More-
over, there is a weak positive correlation between serum
Apelin concentrations and tumor Apelin expression
levels [20]. In this study, we enrolled GC patients to fur-
ther investigate the role of tumor and serum Apelin in
the clinical features, in particular, disease characteristics
and prognosis in GC patients.
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Tumor samples and matched adjacent non-tumorous
tissues were collected from 270 patients with GC receiv-
ing surgical resection between 1 January 2009 and 31
December 20013. None of the patients with carcinomas
underwent either chemotherapy or radiotherapy before
surgery. The tumor stage of patients was determined by
the UICC-TNM classification. All the tissue samples
were identified by clinical pathologist and then were
fixed by formaldehyde and embedded by paraffin for fur-
ther study. We also collected tissue samples from 81 pa-
tients with chronic gastritis as control. All patients were
followed by consulting their documents, or through
clinic visit or telephone interviews. Overall survival (OS)
period was defined as the time interval between the date
of surgery and date of death or last follow-up.
Immunohistochemistry
GC tissues sections fixed by formalin and embedded by
paraffin were dewaxed in xylene and rehydrated with gradi-
ent ethanol. The sections were incubated with rabbit anti-
Apelin monoclonal antibody (1:150, Abcam, USA) at 4 °C
overnight. The immune complex was detected by a stand-
ard avidin-biotin detection system (Dako, USA). The sec-
tions were evaluated by three pathologists who were
blinded to clinicopathologic information. Apelin staining
score = positive cell score + staining intensity score. The
percentage of positive cells was classified by four grades
(percentage scores): 0 [21], <1/3 [21], 1/3-2/3 [22] and >2/3
[22]. The intensity of staining was also divided into four
grades (intensity scores): no staining [21], weak staining
[21], moderate staining [22] and strong staining [22]. The
overall scores 0, 1–2, 3–4, and 5–6 were defined as negative
(−), weak positive (±), moderate positive (+), and strong
positive (++) respectively.
Serum apelin level detection
The peripheral blood samples were collected from all
participants after 12-h overnight fast. The serum Apelin
concentration was measured by an ELISA kit (Apelin-12,
Phoenix pharmaceuticals, Belmont, USA) according to
manufacturer’ protocol. The sensitivity was 0.05 ng/mL,
and intra- and inter-assay variations were <5 and <10 %,
respectively.
Cell lines and cell culture
Three GC cell lines, namely, SGC-7901, MKN-45, AGS
and an immortalized normal gastric epithelial cell line
GES-1, were purchased from Cell Bank of Type Culture
Collection (Shanghai China). Cells were maintained in
Dulbecco’s Modified Eagle’s medium (DMEM, Gibco)
containing 10 % fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 ug/ml streptomycin.
Gene silencing of APJ with siRNA
GC cell lines were transfected with 200 nmol/L APJ or
nonspecific siRNA (Ambion, USA) in culture medium
for 48 h. The medium was then replaced with fresh
DMEM and the cells were incubated at 37 °C for an
additional 24 h. The cells were collected and stored at
−80 °C until assayed for protein expression by Western
blotting as detailed below.
Proliferation assay
The effect of hypoxia on the viability of cultured cells
was evaluated by 2-(2-methoxy-4-nitrophenyl)-3-(4-ni-
trophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, a
monosodium salt (WST-8) assay (Dojindo Molecular
Technologies, Japan). Briefly, cells are treated with Apelin
(50 and 100 ng/mL) and seeded (cell density of 5 × 103 per
well) in 96-well microplates and cultured in the hypoxic
incubator for 8 h, followed by addition of 10 ul WST-8
solution to each well. After 4 h of incubated at 37 °C,
absorbance was measured at 450 nm using a microplate
reader (Benchmark Microplate Reader, BIO-RAD) with a
reference wavelength of 490 nm.
Cell migration and invasion analysis
Cells were treated with Apelin (50 and 100 ng/mL) for
cell migration and invasion assay by using Transwell
chamber (Corning, NY, USA), which coated with Matri-
gel (BD Bioscience) in invasion assays. 5 × 104 cells were
collected and seeded in the upper chamber without
serum. 10 % fetal bovine serum was used as a chemo-
attractant in lower chamber. After 8 h of incubation,
cells that did not invade through the pores were wiped
out with cotton wool. Invaded cell was stained with
20 % methanol and 0.2 % crystal violet and counted with
an inverted microscope (Olympus, Japan).
Western blot analysis
Cells were lysed with RIPA lysis buffer and the lysates
protein concentration was measured by a BCA Protein
Assay Kit (Pierce, Rockford, USA). The protein samples
(10 μg/well) were loaded onto 10 % SDS-PAGE and then
transferred onto PVDF membranes. After blocked by
skim milk, the membranes were incubated in the pri-
mary antibodies for overnight at 4 °C and then in the
HRP-conjugated secondary antibody for 2–3 h at room
temperature. The primary antibodies used in the experi-
ments were anti-Apelin, anti-APJ (both 1:1000; Abcam,
USA), anti- Matrix metalloproteinases1 (MMP1) and
MMP9 (both 1:1000; Santa Cruz, USA), anti-Bone mor-
phogenetic protein 2 (BMP2, 1:1000; Santa Cruz, USA),
anti-interleukin1 and 6 (IL1 and IL6, both1:1000; Santa
Cruz, USA), Finally the protein band images were cap-
tured by ECL reagent (Thermo, USA).
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Statistical analysis
All data were analyzed using the SPSS 19.0 software
(SPSS Inc., Chicago, USA) and GraphPad Prism (Version
6.02 for Windows, Graphpad Software, USA). Qualita-
tive variables were analyzed using either the Chi Square
Test or the Fisher’s test. Correlations between Apelin ex-
pression and clinical features of GC patients were deter-
mined by chi-square test. Survival analysis was
performed using the Kaplan-Meier method. COX ana-
lysis was used to determine the independent prognostic
factor for GC patients. Unless otherwise noted, P < 0.05
was accepted as significant.
Results
The demographical information of patients with GC and
patients with chronic gastritis listed in Table 1. There is
no significant difference in mean age, gender distribu-
tion, smoking status and Helicobacter Pylori infection
status between two groups.
The representative images about Apelin immunohisto-
chemical stainings are shown in Fig. 1a. Apelin is
expressed in cytoplasma and also in vascular endothelial
cells in the tumor tissue. Cytoplasmic Apelin staining
was identified in 112 of 270 normal gastric mucosa sam-
ples and 36 of 81 samples with chronic gastritis (41.2 %
vs.44.4 %, P = 0.635). The GC patients with strong Ape-
lin staining (show as “++” in Table 1) are 120, with mod-
erate Apelin staining are 99 (show as “+” in Table 1),
and only 51 patients had weak or no Apelin staining in
this group (show as “±/-” in Table 1). There are a signifi-
cant difference in Apelin expression status between pa-
tients with GC and with chronic gastritis (Table 2).
In contrast, the serum Apelin levels remains similar
among GC and Chronic gastritis groups (2.84 ± 1.13
vs.2.52 ± 0.78, ng/mL, P = 0.453, Fig. 1).
We next investigated the relationship between tumor
Apelin expression status and clinical characteristics of
GC patients. As shown in Table 3, high expression of
Apelin in GC cancer samples was associated with poor
differentiation, tumor stage, lymph node metastases, and
distant metastases. However, there were no significant
associations between Apelin expression levels and gen-
der, age, or histology type and tumor size was found
(Table 3). When the serum Apelin is studied, we only
found that GC patients with lymph node metastasis had
a higher serum Aplein level compared to those without
(P = 0.043). However, serum Apelin levels are not associ-
ated with the other clinical characteristics in GC patients
(All P > 0.05, Table 3).
Table 1 The demographical data of patients with GC cancer
and chronic gastritis
Variables Patients with GC Patients with
chronic gastritis
P value
Age (years) 55.6 ± 5.4 55.5 ± 6.3 0.236
Gender
Male 144 35 0.109
Female 126 46
Smoking status




Presence 187 57 0.87
Absence 83 24
HP Helicobacter Pylori
Fig. 1 a shows the representative images about Apelin
immunohistochemical stainings. Left, high Apelin expression sample.
Apelin is expressed in cytoplasma and also in vascular endothelial
cells in the tumor tissue. Right, low Apelin expression sample, Apelin
are dominately expressed in vascular endothelial cells. b The serum
Apelin levels between patients with GC and chronic gastritis. There
is no significant difference in serum Apelin levels between two
groups (2.84 ± 1.13 vs.2.52 ± 0.78, ng/mL, P = 0.453)
Table 2 The APELIN expression status among GC cancer











++ 120 48 25 <0.001
+ 99 89 11
±/- 51 133 45
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We further analyzed the relation of tumor Apelin ex-
pression status with the survival of GC patients in this
study. As shown in Fig. 2a, patients with high tumor Ape-
lin staining had a significantly shorter overall survival
period compared to those with low Apelin expression and
those with weak or negative Apelin staining (22.6 ± 4.9,
29.1 ± 3.7 and 30.4 ± 6.4, months, P < 0.001 by log-rank
test, Fig. 2a). We used the mean serum Apelin value
(2.84 ng/mL) as a cut-off value to subgroup all GC
patients: those with equal or higher than 2.84 ng/mL were
assigned into high serum Apelin group (n = 160) and
those with lower than 2.84 ng/mL were assigned into
low serum Apelin group (n = 110). We found these
two groups had similar overall survival period (26.9 ±
5.2 vs. 26.4 ± 2.9, months, P = 0.187 by log-rank test,
Fig. 2b).
Subsequently, as shown in Table 4, the univariate
COX analysis revealed that the prognosis of GC patients
were associated with lymph node metastasis (P = 0.004),
tumor differentiation (P = 0.034) and tumor Apelin ex-
pression (P = 0.002), but not with serum Apelin level (P
= 0.332). Furthermore, the multivariate mode of COX
analysis revealed that tumor Apelin expression level
wasn a independent prognostic factor for the overall sur-
vival in GC patients (P = 0.003).
In our in vitro study, we observed that all GC cell
lines, including SGC-7901, MKN-45 and AGS had a 1.5
to 2 folds higher expression levels of Apelin compared
to non-cancer cell line GES-1 (Fig. 3a). Similarly, the
APJ expression level is higher in GC cell lines than in
normal cell line GES-1 (Fig. 3a).
When these cells are treated with Apelin (50 and
100 ng/mL) for 8 h, we observed that proliferation
rates remain similar between GC cell lines and non-
cancer cell line GES-1 (Fig. 3b). However, the migra-
tion and invasion abilities of GC cell lines were sig-
nificantly increased by Apelin treatment (Fig. 3c-d).
Notably, we observed that Apelin treatment induced
the protein expression of a variety of cytokines, such as
APJ, MMP1, MMP9, BMP-2, IL1 and IL6 (Fig. 4a). All
these cytokines are reported associated with tumor inva-
sive or metastasis.
When these cells are transfected with Apelin recep-
tor APJ si-RNA, an 85 % reduction of APJ was ob-
served and Apelin expression was not affected
(Fig. 4b). When the scramble and si-APJ RNA trans-
fected cells were treated with Apelin (100 ug/mL for
24 h), We observed that there is a reduced migration
and invasion abilities in GC cell lines (Fig. 4c and d,
respectively).
Table 3 The association between Tumor and serum Apelin levels and clinical characteristics in GC patients
Variables Number of cases Apelin expression level P value Serum Apelin (ng/mL) P value
++ (n = 120) +(n = 99) -(n = 51)
Gender
male 175 76 69 30 0.377 3.35 ± 1.45 0.345
female 95 44 30 21 3.33 ± 1.37
Age (years)
< 60 171 80 60 31 0.569 3.31 ± 1.76 0.143
> 60 99 40 39 20 3.35 ± 1.77
Tumor size (cm)
< 5 91 39 29 23 0.142 3.29 ± 1.67 0.167
> 5 179 81 70 28 3.38 ± 1.26
Tumor differentiation
Poorly 166 98 58 10 <0.001 3.24 ± 2.01 0.187
Well, moderately 104 22 41 41 3.36 ± 1.555
Tumor stage
T1 + T2 106 13 59 34 <0.001 3.40 ± 2.11 0.057
T3 + T4 164 107 40 17 3.27 ± 1.25
Lymph node metastasis
Negative 90 26 24 40 <0.001 3.27 ± 1.62 0.043
Positive 180 94 75 11 3.39 ± 1.28
Distant metastasis
Positive 88 51 21 16 0.004 3.34 ± 1.87 0.787
Negative 182 69 78 35 3.34 ± 0.87
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Discussion
In the present study, we studied the correlation between
tissue and serum Apelin level with the clinical character-
istics and prognosis of GC patients. Our data show that
tissue Apelin expression status, instead of serum Apelin
level, is closely associated with more advance clinical
features and poorer outcome. Our in vitro data further
reveals that GC cell lines over-expression Aplein and its
receptor APJ, together with the other cytokines which
are known to facilitate tumor metastasis and progres-
sion, including IL-1, IL6, MMP1, MMP9 and BMP-2.
The inhibition of Apelin receptor APJ, reduces the cellu-
lar migration and invasion abilities in vitro. Our data
suggest that tumor Apelin is a protein marker to evalu-
ate the clinical features and to predict post-operative
prognosis in GC patients.
Apelin is a peptide expressed in various tissues, in-
cluding gastrointestinal tract, heart, lung, liver, and bone
[23]. Previous experimental and clinical studies suggest
that Apelin is a mitogenic factor for the endothelial cells
and stimulates tumor angiogenesis. Recent studies show
that Apelin was found to be up-regulated in a variety of
human cancers. The Apelin/APJ pathway induces arter-
iogenesis in samples of poorly-differentiated hepatocellu-
lar carcinoma (HCC) [24]. Using Apelin as a marker to
monitor tumor vessel normalization window during
anti-angiogenic therapy was reported [17]. Co-
expression of Apelin and APJ in tumor is the basis of an
autocrine loop involved in the growth of colon adeno-
carcinomas [25]. A clinical study showed that Apelin up-
regulation is associated with a poor prognosis in oral
squamous cell carcinoma patients [24]. However, the
role of Apelin in GC is not adequately studied to date.
A recent study detected the serum Apelin level in gas-
troesophageal cancer (GEC) patients and found that
serum Apelin was significantly higher in cachectic pa-
tients than in the controls. Serum Apelin is positively
correlated with hypersensitive C reactive protein level,
suggesting that suggest that Apelin production in serum
is probably related to systemic inflammatory response in
GEC patients [20]. However, this study did not investi-
gate the prognostic role of Apelin in GC patients. Given
serum marker could be easily affected by external condi-
tion, such as inflammation and stress, it is of interest to
Fig. 2 The relation of tumor Apelin expression status with the survival of GC patients by Kaplan-Miere curves. a Patients with strong Apelin staining
had significantly shorter overall survival period 22.6 ± 4.9 months) compared to those with low Apelin expression (29.1 ± 3.7, months) and those with
weak or negative Apelin staining (30.4 ± 6.4 months). b GC patients with high and low serum Apelin had similar overall survival period (26.9 ± 5.2 vs.
26.4 ± 2.9, months, P = 0.187 by log-rank test, Fig. 2b)
Table 4 The Cox analysis of prognostic factors for GC patients
Univariate COX analysis Multivariate COX analysis
Variable HR 95 % CI P-value HR 95 % CI P-value
Lymph node metastasis 2.43 1.44–4.67 0.004 1.67 1.23–3.87 0.024
Tumor differentiation 1.59 1.17–2.89 0.034 1.53 1.10–2.98 0.021
Tumor APJ level 2.23 1.451–4.14 0.002 2.15 1.33–4.32 0.003
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study the effect of tumor Aplein in tumor tissues in GC
patients. In our study, we found that GC patients had a
significantly higher percentage of having strong Apelin
staining than samples from chronic gastritis. However,
the serum Apelin levels remains similar among GC and
Chronic gastritis groups. Moreover, high expression of
Apelin in GC cancer samples was associated with poor
differentiation, lymph node metastases and distant me-
tastases. However, serum Apelin levels are not associated
with the other clinical characteristics in GC patients.
In this study, we detected several cytokines, including
IL-1, IL6, MMP1, MMP9 and BMP-2. There factors are
known to be correlated with tumor invasiveness and me-
tastasis in gastric cancer [25–29]. We observed GC cell
lines had a higher expression of these factor and their ex-
pression can be further increased by Apelin treatment.
We postulate that Apelin may prompt tumor invasiveness
through up-regulation of these factors.
Recent animal studies indicated that lymphatic vessels
interact extensively with malignant cells. Moreover, lym-
phangiogenesis is associated with lymph node metasta-
sis. Apelin overexpression induces intratumoral
lymphangiogenesis and promotes lymphatic metastasis.
Apelin increases lymphatic endothelial cells (LEC)
spheroid numbers and stimulates capillary-like cord
formation of LECs in vitro and promotes the growth of
lymph vessels [18]. Consistent with these findings, in
this study, we found that tumor Apelin was associated
with lymph node metastases.
A previous study suggest that tumor patients had
higher Apelin levels compared with healthy controls,
and Apelin is closely related to the disease stages and
progression independently of other potential con-
founders [30]. Apelin was expressed in cultured lung
cancer cell lines both at the mRNA and protein levels
[30]. We observed similar phenomena in cultured GC
cell lines. Increased Apelin protein level is associated
with elevated microvessel densities and predicts poor
overall survival, suggesting Apelin as a novel angiogenic
factor in human lung cancer cell [31]. In our study we
observed that GC patients with strong Apelin staining
had significantly shorter overall survival period com-
pared to those with low Apelin expression and those
with weak or negative Apelin staining.
Several limitation should be addressed it this study.
Firstly, the sample size is relatively small and only Chin-
ese patients were enrolled. Secondly, the signal pathway
under which Apelin/APJ pathway affects cellular bio-
logical behavior of gastric cell lines was not included in
this study.
Fig. 3 a SGC-7901, MKN-45 and AGS had a higher Apelin expression levels compared GES-1 by western blot assay. b Apelin treatment (50 and
100 ng/mL) for 8 h did not affect the proliferation rates in GC cell lines and non-cancer cell line GES-1. c and d The migration and invasion
abilities of GC cell lines were significantly increased by Apelin treatment (50 and 100 ng/mL for 8 h, respectively)
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Conclusion
In the present study, we reported that tissue Apelin sta-
tus, rather than serum Apelin level, is closely associated
with clinical features and prognosis of GC patietns. in
vitro study indicated in GC cell lines inhibition of APJ
reduced cellular proliferation rate, migration and inva-
sion ability in vitro, suggesting the involvement of
Apelin/APJ pathway in GC progression.
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